STING‐ATF3/type I interferon crosstalk: A potential target to improve anti‐tumour immunity in chemotherapy‐treated urothelial carcinoma-Reference-Cited by-同舟云学术

STING‐ATF3/type I interferon crosstalk: A potential target to improve anti‐tumour immunity in chemotherapy‐treated urothelial carcinoma

Published:2024-09 Issue:9 Volume:14 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Fauvre Alexandra¹,Machu Margot¹,Merienne Audrey²,Vie Nadia¹,Bessede Thomas¹,Robin Mathilde¹,Garambois Veronique¹,Taffoni Clara³,Laguette Nadine³,Gervois‐Segain Nadine²,Jarry Anne²,Labarriere Nathalie²,Allory Yves⁴,Larbouret Christel¹,Gros Laurent¹,Tosi Diego¹,Solit David B.⁵,Pourquier Philippe¹,Houédé Nadine¹,Gongora Celine¹^ORCID

Affiliation:

1. IRCM Univ Montpellier, Inserm, ICM, CNRS Montpellier France

2. Nantes Université, Univ Angers, INSERM, CNRS Nantes France

3. IGMM, Université de Montpellier, CNRS Montpellier France

4. Institut Curie Paris France

5. Weill Cornell Med Coll New York New York USA

Funder

Agence Nationale de la Recherche

Institut National Du Cancer

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.70011

Reference6 articles.

1. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature

2. UPPER TRACT UROTHELIAL NEOPLASMS: INCIDENCE AND SURVIVAL DURING THE LAST 2 DECADES

3. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment;Tosi D;BMC Cancer,2018

4. The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer

5. Type I interferons and cancer: an evolving story demanding novel clinical applications;Aricò E;Cancers,2019